Original Research
Published on 14 Oct 2025
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China
in Health Economics
- 204 views
Original Research
Published on 14 Oct 2025
in Health Economics
Original Research
Published on 14 Oct 2025
in Artificial Intelligence in Radiology
Original Research
Published on 14 Oct 2025
in Water and Human Systems
Editorial
Published on 14 Oct 2025
in Applied Neuroimaging
Original Research
Published on 14 Oct 2025
in Sustainable and Intelligent Phytoprotection
Review
Published on 14 Oct 2025
in Microbes and Innate Immunity
Editorial
Published on 14 Oct 2025
in Healthcare Professions Education
Original Research
Published on 14 Oct 2025
in Culture and Communication
Original Research
Published on 14 Oct 2025
in Medicine and Public Health
Review
Published on 14 Oct 2025
in Molecular Innate Immunity
Case Report
Published on 14 Oct 2025
in Surgical Oncology
Editorial
Published on 14 Oct 2025
in Pharmacology of Infectious Diseases
Original Research
Published on 14 Oct 2025
in Orthopedic Surgery
Review
Published on 14 Oct 2025
in Public Health Policy
Original Research
Published on 14 Oct 2025
in Hematology
Review
Published on 14 Oct 2025
in Orthopedic Surgery